BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Jun 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
NOVOLOG FLEXPEN (water injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NovoLog FlexPen is a rapid-acting insulin analog (insulin aspart) delivered via prefilled subcutaneous injection pen for glycemic control in diabetes. It is indicated for patients with type 1 and type 2 diabetes who require insulin therapy. The drug works by mimicking the body's natural rapid insulin response, enabling faster glucose uptake after meals.
$1.9BPart D
LOE ApproachingAs a mature product approaching loss of exclusivity with $1.9B in annual spending, the brand team is likely transitioning from growth-focused roles to retention and lifecycle management strategies.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Investigation of the Analgesic Effects of Intradermal and Subdermal Sterile Water Injection on Active Labor Pain
Started Jan 2024
Why This Matters for Your Career
$1.9B Medicare spend — this is a commercially significant brand
Worked on NOVOLOG FLEXPEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.